The Loudness Dependence of Auditory Evoked Potentials (LDAEP) as an Indicator of Serotonergic Dysfunction in Patients with Predominant Schizophrenic Negative Symptoms

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Wyss, Christine ^a   Hitz, Konrad ^a   Hengartner, Michael P ^a   Theodoridou, Anastasia ^a   Obermann, Caitriona ^a   Uhl, Idun ^b   Roser, Patrik ^b   Grünblatt, Edna ^c   Seifritz, Erich ^a   Juckel, Georg ^b   Kawohl, Wolfram ^a  

^a UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; NICOTINE; SEROTONIN;

ADULT; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; ELECTROENCEPHALOGRAM; EVOKED AUDITORY RESPONSE; HUMAN; LEFT HEMISPHERE; LOUDNESS DEPENDENCE AUDITORY EVOKED POTENTIAL; MALE; NEGATIVE SYNDROME; RIGHT HEMISPHERE; SEROTONIN BRAIN LEVEL; SEROTONINERGIC DYSFUNCTION; SEROTONINERGIC SYSTEM; SEROTONINERGIC TRANSMISSION;

ADULT; CEREBRUM; DEMOGRAPHY; ELECTRODES; EVOKED POTENTIALS, AUDITORY; FEMALE; HUMANS; LOUDNESS PERCEPTION; MALE; SCHIZOPHRENIA; SEROTONIN;

EID: 84880064299     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068650     Document Type: Article

References (76)

1. Andreasen NC (1989) The Scale for the Assessment of Negative Symptoms (Sans)- Conceptual and Theoretical Foundations. Br J Psychiatry 155, Supp No. 7- Negative Symptoms in Schizophrenia: 49-52.
2. American Psychological Association (2000) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). Washington: American Psychiatric Association. p. 299.
3. Andreasen NC, (1982) Negative Symptoms in Schizophrenia- Definition and Reliability. Arch Gen Psychiatry 39: 784-788.
4. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR, (2006) The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 32: 214-219.
5. Häfner H, Löffler W, Maurer K, Hambrecht M, van der Heiden W, (1999) Depression, negative symptoms, social stagnation and social decline in the early course of schizophrenia. Acta Psychiatr Scand 100: 105-118.
6. Rössler W, Salize HJ, van Os J, Riecher-Rössler A, (2005) Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 15: 399-409.
7. Davis KL, Kahn RS, Ko G, Davidson M, (1991) Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474-1486.
8. Grace AA, (1991) Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 41: 1-24.
9. Knable MB, Weinberger DR, (1997) Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol (Oxf) 11: 123-131.
10. Weinberger DR, (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44: 660-669.
11. Abi-Dargham A, (2007) Alterations of serotonin transmission in schizophrenia. Int Rev Neurobiol 78: 133-164.
12. Breier A, (1995) Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res 14: 187-202.
13. Kapur S, Remington G, (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466-476.
14. Meltzer HY, (1989) Clinical-Studies on the Mechanism of Action of Clozapine- the Dopamine-Serotonin Hypothesis of Schizophrenia. Psychopharmacology (Berl) 99: 18-27.
15. Roth B, Meltzer H (2000) The role of serotonin in schizophrenia. In: Meltzer H, editor. Psychopharmacology: The Fourth Generation of Progress. New York: Raven. 575-583 p.
16. Davis JM, Chen N, Glick ID, (2003) A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553-564.
17. Leucht S, Heres S, Kissling W, Davis JM, (2011) Evidence-based pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol 14: 269-284.
18. Miyamoto S, Duncan GE, Marx CE, Lieberman JA, (2004) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10: 79-104.
19. Rummel-Kluge C, Kissling W, Leucht S, (2006) Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev: John Wiley & Sons, Ltd. (3): CD005581 DOI:10.1002/14651858.CD005581.pub2.
20. Silver H, (2004) Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Opin Pharmacother 5: 2053-2058.
21. Singh SP, Singh V, Kar N, Chan K, (2010) Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry 197: 174-179.
22. Meltzer HY, (1999) The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 21: 106-115.
23. Hegerl U, Juckel G, (2000) Identifying psychiatric patients with serotonergic dysfunctions by event-related potentials. World J Biol Psychiatry 1: 112-118.
24. Juckel G, Pogarell O, Augustin H, Mulert C, Müller-Siecheneder F, et al. (2007) Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder. J Clin Psychiatry 68: 1206-1212.
25. Hegerl U, Gallinat J, Juckel G, (2001) Event-related potentials: Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J Affect Disord 62: 93-100.
26. Juckel G (2005) Serotonin und akustisch evozierte Potentiale: Darmstadt: Steinkopff Verlag. 1-203.
27. Quednow BB, Treyer V, Hasler F, Dörig N, Wyss MT, et al. (2012) Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. Neuroimage 59: 3922-3932.
28. Hegerl U, Juckel G, (1993) Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis. Biol Psychiatry 33: 173-187.
29. Hegerl U, Juckel G, (1994) Auditory-Evoked Dipole Source Activity- Indicator of Central Serotonergic Dysfunction in Psychiatric-Patients. Pharmacopsychiatry 27: 75-78.
30. Kawohl W, Hegerl U, Müller-Oerlinghausen B, Juckel G, (2008) Insights in the central serotonergic function in patients with affective disorders. Neuropsychiatr 22: 23.
31. Lee IH, Yang YK, Chen PS, Huang HC, Yeh TL, et al. (2011) Loudness dependence of auditory evoked potentials (LDAEP) correlates with the availability of dopamine transporters and serotonin transporters in healthy volunteers- a two isotopes SPECT study. Psychopharmacology (Berl) 214: 617-624.
32. O'Neill BV, Croft RJ, Nathan PJ, (2008) The loudness dependence of the auditory evoked potential (LDAEP) as an in vivo biomarker of central serotonergic function in humans: rationale, evaluation and review of findings. Hum Psychopharmacol 23: 355-370.
33. Hitz K, Heekeren K, Obermann C, Huber T, Juckel G, et al. (2011) Examination of the effect of acute levodopa administration on the loudness dependence of auditory evoked potentials (LDAEP) in humans. Psychopharmacology (Berl) 221: 389-96.
34. Juckel G, Kawohl W, Giegling I, Mavrogiorgou P, Winter C, et al. (2008) Association of catechol-O-methyltransferase variants with loudness dependence of auditory evoked potentials. Hum Psychopharmacol 23: 115-120.
35. Kawohl W, Giegling I, Mavrogiorgou P, Pogarell O, Mulert C, et al. (2008) Association of functional polymorphisms in NOS1 and NOS3 with loudness dependence of auditory evoked potentials. Int J Neuropsychopharmacol 11: 477-483.
36. O'Neill BV, Croft RJ, Leung S, Oliver C, Phan KL, et al. (2007) High-dose glycine inhibits the loudness dependence of the auditory evoked potential (LDAEP) in healthy humans. Psychopharmacology (Berl) 195: 85-93.
37. Gudlowski Y, Ozgurdal S, Witthaus H, Gallinat J, Hauser M, et al. (2009) Serotonergic dysfunction in the prodromal, first-episode and chronic course of schizophrenia as assessed by the loudness dependence of auditory evoked activity. Schizophr Res 109: 141-147.
38. Juckel G, Gallinat J, Riedel M, Sokullu S, Schulz C, et al. (2003) Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity. Schizophr Res 64: 115-124.
39. Juckel G, Gudlowski Y, Muller D, Ozgurdal S, Brune M, et al. (2008) Loudness dependence of the auditory evoked N1/P2 component as an indicator of serotonergic dysfunction in patients with schizophrenia- A replication study. Psychiatry Res 158: 79-82.
40. Park YM, Lee SH, Kim S, Bae SM, (2010) The loudness dependence of the auditory evoked potential (LDAEP) in schizophrenia, bipolar disorder, major depressive disorder, anxiety disorder, and healthy controls. Prog Neuropsychopharmacol Biol Psychiatry 34: 313-316.
41. World Health Organization (1993) The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: World Health Organization. 28-29, 78-88.
42. Kay SR, Fiszbein A, Opler LA, (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
43. Hamilton M, (1960) A Rating Scale for Depression. J Neurol Neurosurg Psychiatry 23: 56-62.
44. Bech P, Rafaelsen OJ, (1980) The Use of Rating-Scales Exemplified by a Comparison of the Hamilton and the Bech-Rafaelsen Melancholia Scale. Acta Psychiatr Scand 62: 128-132.
45. Addington D, Addington J, Schissel B, (1990) A Depression Rating-Scale for Schizophrenics. Schizophr Res 3: 247-251.
46. Möller H-J, Müller WE, Bandelow B (2001) Neuroleptika, Pharmakologische Grundlagen, klinisches Wissen und therapeutisches Vorgehen: Stuttgart: Wissenschaftliche Verlagsgesellschaft. p. 243.
47. Schechter G, Buchsbaum M, (1973) The effects of attention, stimulus intensity, and individual differences on the average evoked response. Psychophysiology 10: 392-400.
48. Baribeau JC, Laurent JP (1987) The effect of selective attention on augmenting/intensity function of the early negative waves of AEPs. Electroencephalogr Clin Neurophysiol Suppl 40: 68-75.
49. Jasper HH, (1958) The ten-twenty electrode system of the International Federation. Electroencephalogr Clin Neurophysiol 10: 380-375.
50. Scherg M, Vajsar J, Picton TW, (1989) A Source Analysis of the Late Human Auditory Evoked Potentials. J Cog Neurosci 1: 336-355.
51. Hegerl U, Gallinat J, Mrowinski D, (1994) Intensity dependence of auditory evoked dipole source activity. Int J Psychophysiol 17: 1-13.
52. Kawohl W, Waberski TD, Darvas F, Norra C, Gobbel R, et al. (2007) Comparative source localization of electrically and pressure-stimulated multichannel somatosensory evoked potentials. J Clin Neurophysiol 24: 257.
53. Waberski TD, Gobbele R, Kawohl W, Cordes C, Buchner H, (2003) Immediate cortical reorganization after local anesthetic block of the thumb: source localization of somatosensory evoked potentials in human subjects. Neurosci Lett 347: 151-154.
54. Bruneau N, Roux S, Garreau B, Lelord G, (1985) Frontal auditory evoked potentials and augmenting-reducing. Electroencephalogr Clin Neurophysiol 62: 364-371.
55. Yamaguchi S, Knight RT, (1990) Gating of somatosensory input by human prefrontal cortex. Brain Res 521: 281-288.
56. Beauducel A, Debener S, Brocke B, Kayser J, (2000) On the reliability of augmenting/reducing. Int J Psychophysiol 14: 226-240.
57. Hegerl U, Prochno I, Ulrich G, Müller-Oerlinghausen B, (1988) Are auditory evoked potentials suitable for predicting the response to lithium prophylaxis? A study on the effects of repeated measurement, age, gender, and personality on the amplitude/stimulus intensity function in healthy volunteers. Pharmacopsychiatry 21: 336-337.
58. Hagenmuller F, Hitz K, Darvas F, Kawohl W, (2011) Determination of the loudness dependence of auditory evoked potentials: single-electrode estimation versus dipole source analysis. Hum Psychopharmacol 26: 147-154.
59. Hoffman JP (2004) Generalized linear models: an applied approach. Boston, MA: Pearson. 1-216.
60. Cook IA, (2008) Biomarkers in psychiatry: potentials, pitfalls, and pragmatics. Prim psychiatry 15: 54.
61. Simmons JG, Nathan PJ, Berger G, Allen NB, (2011) Chronic modulation of serotonergic neurotransmission with sertraline attenuates the loudness dependence of the auditory evoked potential in healthy participants. Psychopharmacology (Berl) 217: 101-110.
62. Hensch T, Herold U, Diers K, Armbruster D, Brocke B, (2008) Reliability of intensity dependence of auditory-evoked potentials. Clin Neurophysiol 119: 224-236.
63. Jaworska N, Blier P, Fusee W, Knott V, (2012) Scalp-and sLORETA-derived loudness dependence of auditory evoked potentials (LDAEPs) in unmedicated depressed males and females and healthy controls. Clin Neurophysiol 123: 1769-1778.
64. Oliva JL, Leung S, Croft RJ, O'Neill BV, Stout JC, et al. (2011) Evidence for sex differences in the loudness dependence of the auditory evoked potential in humans. Hum Psychopharmacol 26: 172-176.
65. Hashimoto T, Kitamura N, Kajimoto Y, Shirai Y, Shirakawa O, et al. (1993) Differential changes in serotonin 5-HT 1A and 5-HT 2 receptor binding in patients with chronic schizophrenia. Psychopharmacology (Berl) 112: 35-39.
66. Yasuno F, Suhara T, Ichimiya T, Takano A, Ando T, et al. (2004) Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol Psychiatry 55: 439-444.
67. Reynolds GP, Yao Z, Zhang X, Sun J, Zhang Z, (2005) Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response. Eur Neuropsychopharmacol 15: 143-151.
68. Goff DC, Evins AE, (1998) Negative symptoms in schizophrenia: neurobiological models and treatment response. Harv Rev Psychiatry 6: 59-77.
69. Winograd-Gurvich C, Fitzgerald PB, Georgiou-Karistianis N, Bradshaw JL, White OB, (2006) Negative symptoms: A review of schizophrenia, melancholic depression and Parkinson's disease. Brain Res Bull 70: 312-321.
70. Linka T, Müller BW, Bender S, Sartory G, (2004) The intensity dependence of the auditory evoked N1 component as a predictor of reponse to Citalopram treatment in patients with major depression. Neurosci Lett 367: 375-378.
71. Salisbury DF, Kuroki N, Kasai K, Shenton ME, McCarley RW, (2007) Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch Gen Psychiatry 64: 521-529.
72. Shenton ME, Dickey CC, Frumin M, McCarley RW, (2001) A review of MRI findings in schizophrenia. Schizophr Res 49: 1-52.
73. Bozikas VP, Kosmidis MH, Kioperlidou K, Karavatos A, (2004) Relationship between psychopathology and cognitive functioning in schizophrenia. Compr Psychiatry 45: 392-400.
74. Okubo Y, Suhara T, Suzuki K, Kobayashi K, Inoue O, et al. (2000) Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci 66: 2455-2464.
75. Flaum M, Andreasen N, (1995) The reliability of distinguishing primary versus secondary negative symptoms. Compr Psychiatry 36: 421-427.
76. Lindenmayer JP, Harvey PD, Khan A, Kirkpatrick B, (2007) Schizophrenia: Measurements of Psychopathology. Psychiatr Clin North Am 30: 339-363.